# US 2025/0144225 A1 · KRAS Proteolysis Targeting Chimeras

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144225 A1
- Document ID: US20250144225A1
- Status: Published application
- Kind: A1
- Application number: 18/904,330
- Filed: 2024-10-02
- Published: 2025-05-08
- Earliest claimed: 2023-10-03
- Assignees: PAQ Therapeutics Inc.
- Applicants: PAQ Therapeutics Inc.
- Inventors: Nan Ji; Hui Qiu; Ruoxi Lan
- Web page: https://patentgrep.com/patent/US20250144225A1

## CPC

- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are KRAS proteolysis targeting chimeras (PROTACs), compositions comprising the KRAS PROTACs, and methods of making and using the KRAS PROTACs, e.g., to promote degradation of KRAS and/or treat KRAS-associated cancers. In an embodiment, the KRAS PROTAC has the following structural formula: or a pharmaceutically acceptable salt thereof, wherein values for the variables are as described herein.

## Claims

### Claim 1

A compound of the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is
Ring A is (C5-C12) heterocyclyl;
R5′ is hydroxy, —NH2, cyano, fluoro, or hydrogen;
R5″ is hydrogen, halo, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6) hydroxyalkyl, or (C1-C6) cyanoalkyl;
each R6 is independently halo, cyano, hydroxy, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6) hydroxyalkyl, or (C1-C6) cyanoalkyl;
n is 1 or 2;
m is 0, 1, 2, or 3;
X1 is N or C(R10);
R10 is hydrogen, halogen, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C2-C6)alkenyl, (C2-C6)alkynyl, —CN, (C1-C6)alkoxy, —S—(C1-C6)alkyl or —S—(C1-C6)haloalkyl;
Y′ is —(C1-C3)alkylene-O-#, (C1-C3)alkylene-N(H)-#, or (C1-C3)alkylene-N ((C1-C3)alkyl)-#, or is absent;
# indicates point of attachment of Y′ to L′;
R3 is (C6-C14)aryl or (C5-C14) heteroaryl, wherein the (C6-C14)aryl or
(C5-C14) heteroaryl is optionally substituted with one or more R14;
R4 is hydrogen, halogen or (C1-C3)alkyl;
each R14 is independently halogen, cyano, hydroxy, (C1-C4)alkyl, —S—(C1-C3)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C2-C4) hydroxyalkynyl, (C1-C3) cyanoalkyl, triazolyl, (C1-C3)haloalkyl, —O—(C1-C3)haloalkyl, —S—(C1-C3)haloalkyl,
(C1-C3)alkoxy, (C1-C3) hydroxyalkyl, —CH2C(O)N(R11)2, (C3-C4)alkynyl-N(R11)2, N (R11)2, deutero (C2-C4)alkynyl, (C1-C3)alkoxy (C1-C3)haloalkyl, or
(C3-C6) cycloalkyl, wherein the (C3-C6) cycloalkyl is optionally substituted with halogen or (C1-C3)alkyl;
L′ is a covalent bond or a bivalent, saturated or unsaturated, straight or branched C1-C25 hydrocarbon chain wherein 0-10 methylenes of L′ are replaced by X;
each X is independently-O—, —N(R)—, —S—, —OC(O)—, —C(O)—, —C(H)(F)—, —C(F)2—, -Cy-, —S(O)—, —S(O)2—, —N(R) S (O)2—, —N(R)C(O)—, —OC(O)N(R)—, —N(R)C(O)N(R)—,
each-Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-11 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
each R is independently hydrogen or (C1-C3)alkyl;
r is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and
Degron is
wherein one or more of the hydrogen atoms on the benzene ring of the Degron is optionally replaced with a fluorine atom,
provided the compound is not
or a salt thereof.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound of claim 1, of the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is
Ring A is (C5-C8) monocyclic heterocyclyl;
R5 is hydrogen, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6) hydroxyalkyl, or (C1-C6) cyanoalkyl;
each R6 is independently halo, cyano, hydroxy, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6) hydroxyalkyl, or (C1-C6) cyanoalkyl;
n is 1 or 2;
m is 0, 1, 2, or 3;
X1 is N or C(R10);
R10 is hydrogen, halogen, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C2-C6)alkenyl, (C2-C6)alkynyl, —CN, (C1-C6)alkoxy, —S—(C1-C6)alkyl or —S—(C1-C6)haloalkyl;
R3 is (C6-C14)aryl or (C5-C14) heteroaryl, wherein the (C6-C14)aryl or (C5-C14) heteroaryl is optionally substituted with one or more R14,
R4 is hydrogen, halogen or (C1-C3)alkyl;
each R14 is independently halogen, cyano, hydroxy, (C1-C4)alkyl, —S—(C1-C3)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C2-C4) hydroxyalkynyl, (C1-C3) cyanoalkyl, triazolyl, (C1-C3)haloalkyl, —O—(C1-C3)haloalkyl, —S—(C1-C3)haloalkyl, (C1-C3)alkoxy, (C1-C3) hydroxyalkyl, —CH2C(O)N(R11)2, (C3-C4)alkynyl-N(R11)2, N (R11)2, deutero (C2-C4)alkynyl, (C1-C3)alkoxy (C1-C3)haloalkyl, or (C3-C6) cycloalkyl, wherein the (C3-C6) cycloalkyl is optionally substituted with halogen or (C1-C3)alkyl;
L′ is a covalent bond or a bivalent, saturated or unsaturated, straight or branched C1-C25 hydrocarbon chain wherein 0-10 methylenes of L′ are replaced by X;
each X is independently-O—, —N(R)—, —S—, —OC(O)—, —C(O)—, —C(H)(F)—, —C(F)2—, -Cy-, —S(O)—, —S(O)2—, —N(R) S (O)2—, —N(R)C(O)—, —OC(O)N(R)—, —N(R)C(O)N(R)—,
each-Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-11 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
each R is independently hydrogen or (C1-C3)alkyl;
r is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and
Degron is
wherein one or more of the hydrogen atoms on the benzene ring of the Degron is optionally replaced with a fluorine atom,
provided the compound is not
or a salt thereof.

### Claim at position 4

4-6. (canceled)

### Claim 7 (depends on 3)

The compound of claim 3, wherein Ring A is piperidinyl, morpholinyl, azepanyl, oxazepanyl, or thioazepanyl.

### Claim 8

(canceled)

### Claim 9 (depends on 3)

The compound of claim 3, wherein n is 1.

### Claim at position 8

10-12. (canceled)

### Claim 13 (depends on 3)

The compound of claim 3, wherein R1 is

### Claim 14 (depends on 1)

The compound of claim 1, wherein R1 is:

### Claim at position 11

15-23. (canceled)

### Claim 24 (depends on 3)

The compound of claim 3, wherein X1 is N.

### Claim 25 (depends on 3)

The compound of claim 3, wherein X1 is C(R10), and R10 is hydrogen, fluoro, chloro, methyl, —CF3, —OCF3, —CN, —OCH3, —SCH3, or —SCF3.

### Claim 26

(canceled)

### Claim 27 (depends on 3)

The compound of claim 3, wherein R3 is (C6-C14)aryl optionally substituted with one or more R13, and each R14 is independently halogen, hydroxy, (C1-C4)alkyl, —S—(C1-C3)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C3)alkoxy, (C1-C3) hydroxyalkyl, or deutero (C2-C4)alkynyl.

### Claim 28

(canceled)

### Claim 29 (depends on 27)

The compound of claim 27, wherein R3 is

### Claim 30 (depends on 29)

The compound of claim 29, wherein R3 is

### Claim 31 (depends on 3)

The compound of claim 3, wherein R4 is halogen.

### Claim 32 (depends on 3)

The compound of claim 3, wherein R4 is fluoro.

### Claim 33

(canceled)

### Claim 34 (depends on 3)

The compound of claim 3, wherein L′ is a bivalent, saturated or unsaturated, straight or branched C1-C15 hydrocarbon chain wherein 1 or 2 methylenes of L′ are replaced by Cy and 1-3 methylenes of L′ are replaced by X, wherein: each X is independently-O—, —C(O)—, —N(R)— or —N(R)C(O)—.

### Claim 35 (depends on 34)

The compound of claim 34, wherein each -Cy- is independently a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and is optionally substituted with fluoro, methyl, —CF3, or —CHF2.

### Claim 36 (depends on 35)

The compound of claim 35, wherein each-Cy- is independently a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1 nitrogen atom and optionally one additional heteroatom selected from nitrogen, oxygen, and sulfur, a 4-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1 nitrogen atom and optionally 1-2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1 nitrogen atom and optionally 1 additional heteroatom independently selected from nitrogen, oxygen, and sulfur, is optionally substituted with fluoro, methyl, —CF3, or —CHF2, and is linked via a nitrogen atom.

### Claim 37 (depends on 34)

The compound of claim 34, wherein each-Cy- is independently selected from cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, 2,3-dihydro-1H-indenylene, piperidinylene, azetidinylene, pyrrolidinylene, piperazinylene, morpholinylene, 1-oxa-4,9-diazaspiro[5.5]undecanylene, 3-azaspiro[5.5]undecanylene, 2-azaspiro[3.3]heptanylene, 2-azaspiro[3.5]nonanylene, 7-azaspiro[3.5]nonanylene, 3-azabicyclo[3.2.1]octanylene, 8-azabicyclo[3.2.1]octanylene, 2-azaspiro[4.5]decanylene, 8-azaspiro[4.5]decanylene, 2,8-diazaspiro[4.5]decanylene, 2,6-diazaspiro[3.5]nonanylene, 1,7-diazaspiro[3.5]nonanylene, 2,7-diazaspiro[3.5]nonanylene, 3,9-diazaspiro[5.5]undecanylene, 2,6-diazaspiro[3.3]heptanylene, 3-azabicyclo[3.1.0]hexanylene, 3-azabicyclo[3.1.1]heptanylene, phenylene, or triazinylene, and is optionally substituted with fluoro, methyl, —CF3, or —CHF2.

### Claim 38

(canceled)

### Claim 39 (depends on 3)

The compound of claim 3, wherein L′ comprises-Cy1—(CH2)-Cy2-, wherein Cy1 and Cy2 are each independently-Cy-.

### Claim 40 (depends on 3)

The compound of claim 3, wherein L′ is (CH2)0-1—C(O)-Cy1—(CH2)0-2-Cy2- or —CH2-Cy1—(CH2)0-2-Cy2—, wherein Cy1 and Cy2 are each independently -Cy-.

### Claim 41 (depends on 40)

The compound of claim 40, wherein L′ is —C(O)-Cy1—(CH2)-Cy2- or —CH2-Cy1—CH2-Cy2—, wherein Cy1 and Cy2 are each independently -Cy-.

### Claim 42 (depends on 3)

The compound of claim 3, wherein R is H.

### Claim at position 31

43-44. (canceled)

### Claim 45 (depends on 3)

The compound of claim 3, wherein Degron is
wherein one or more of the hydrogen atoms on the benzene ring of the Degron is optionally replaced with a fluorine atom.

### Claim at position 33

46-73. (canceled)

### Claim 74

A compound selected from;
or a pharmaceutically acceptable salt thereof.

### Claim 75

A compound selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 76 (depends on 3)

A pharmaceutical composition comprising a compound of claim 3, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 77

(canceled)

### Claim 78 (depends on 3)

A method of reducing a level or activity of a KRAS in a cell expressing the KRAS, comprising contacting the cell with a compound of claim 3, or a pharmaceutically acceptable salt thereof.

### Claim 79 (depends on 3)

A method of reducing a level or activity of a KRAS in a subject in need thereof, comprising administering to the subject an effective amount of a compound of claim 3, or a pharmaceutically acceptable salt thereof.

### Claim 80 (depends on 3)

A method for treating a KRAS-associated cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claim 3, or a pharmaceutically acceptable salt thereof.

### Claim at position 41

81-88. (canceled)

### Claim 89 (depends on 74)

A pharmaceutical composition comprising a compound of claim 74, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 90 (depends on 75)

A pharmaceutical composition comprising a compound of claim 75, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
